Q-omics provides the consensus-scored MIR4449 profile across patient tissues and cancer cell-line models. MIR4449 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIR4449 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, MIR4449 RNA expression shows 6,525 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight BRCA, COAD, and READ as cancer lineages where MIR4449 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4449 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4449 survival associations across molecular data types. MIR4449 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4449 RNA expression–survival associations across cancer types. High MIR4449 expression shows unfavorable associations in KICH, DLBC, UVM, THCA and LUAD, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for MIR4449 RNA expression.
This table summarizes MIR4449 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4449. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4449 shows higher tumor expression in COAD, STAD and CHOL. The COAD box plot shows higher MIR4449 RNA expression in tumor versus normal tissue (log2 FC = +0.659, t-test p = .002).
This table shows molecular features associated with MIR4449 in patient tissues and cancer cell lines. In patient samples, MIR4449 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
